Nervous Disorder TRIZ Cases

Phosphorylated glucocerebrosidase overcomes limited tissue penetration by enhancing cellular uptake and therapeutic efficacy in Gaucher disease treatment.

A Th1 adjuvant vaccine activates the choroid plexus to enable immune cell trafficking.

Specific CD31 peptides inhibit platelet and leukocyte activation to treat thrombotic disorders.

Meteorin protein treats allodynia and hyperalgesia by modulating neuronal excitability, avoiding side effects from conventional analgesics.

Combining highly purified cannabidiol with stiripentol increases response rates in treatment-resistant childhood-onset epilepsy.

Dual antibody therapy targets toxic light chains and CD38 plasma cells, reducing NT-proBNP levels faster than single-agent treatments.

Roseburia hominis compositions modulate the microbiota-gut-brain axis to treat neurodegenerative disorders by reducing proinflammatory molecule activation.

Administering an EGF peptide alone resolves the trade-off between immune suppression and nerve repair by directly activating EGFR to drive remyelination.

Phosphorodiamidate morpholino and 2MOE modifications prevent mRNA degradation while increasing SCN2A expression for neurological disorders.

Transdermal cannabidiol gel bypasses gastrointestinal toxicity while reducing behavioral symptom intensity.

Sequence modifications protect GIP analogues from DPPIV cleavage, extending plasma half-life for diabetes treatment.

A method for producing bicyclic compounds utilizes a Claisen rearrangement reaction sequence to synthesize specific chemical intermediates.

Multiple dosing cycles of quadri-positive stromal cells prevent body weight loss and reduce oxidative stress in spinocerebellar ataxia treatment.

Reducing ALOX5 and FLAP expression via siRNA inhibits ACSL4-independent ferroptosis, addressing neuronal dysfunction in Huntington's disease.

A phosphatidic acid and magnesium composition provides symptom relief for premenstrual syndrome.

Recombinant adeno-associated virus vectors travel via olfactory pathways to deliver lysosomal enzymes directly into the brain.

A pharmaceutical composition using N-palmitoyl serinol to enhance memory and cognitive function.

Targeted peptide insertions in rAAV capsids improve CNS transduction efficiency while maintaining manufacturing precision.

Endogenous ATP1A3 promoter drives specific protein expression in CNS neurons, restoring Na+, K+ ATPase activity and rescuing phenotypic abnormalities.

Folate-conjugated photodynamic agents target cancer cells via receptor-mediated endocytosis, reducing healthy tissue damage.

Verapamil modulates orexin, somatostatin, and dopamine receptors to address unmet needs in obesity and diabetes treatment.

Ligands bind the p62 ZZ domain to activate autophagy, removing cytotoxic protein aggregates that accumulate due to impaired proteasome function.

A transdermal patch converts active substance salts into free bases using alkaline oxides reacting with skin moisture.

Novel queuine mimetic compounds act as substrates for the TGT enzyme to normalize cytokine levels and influence cellular metabolism.

A kidney protective agent binds radiolabeled drugs in circulation to facilitate rapid metabolite excretion and reduce renal accumulation.

Administering negative modulators of the alpha-7 nicotinic receptor targets unique adolescent brain vulnerabilities to prevent adult alcohol use disorders.

Segmented gapmer motifs balance binding affinity and specificity to reduce disease-associated transcripts.

Topical mepyramine blocks Nav1.7 channels and H1 receptors, reducing neuropathic pain without opioid side effects.

Probiotic administration modulates the maternal microbiome to protect offspring neurodevelopment.

Lactic acid bacteria produce adenosine to stimulate host melatonin synthesis in the gastrointestinal tract.

Expressing adenovirus E4ORF1 in neural cells enhances proliferation and axon branching while maintaining cellular identity stability.

Isolated bicyclic compound activates Wnt/β-catenin signaling, treating osteoporosis and obesity while minimizing side effects.

Chenopodium formosanum extract regulates NOS3 and PLAT genes to decompose thrombi without bleeding risks.

Composite immunotoxins target IL-13Rα2-positive pancreatic cancer cells to reduce perineural invasion and associated pain.

Sulfur and selenium cannabinoid compounds modulate receptors, resolving psychotropic side effects while maintaining therapeutic efficacy.

Pre-(γ)pro-GDNF splice variant enables neuronal activity-dependent secretion, resolving safety concerns from constitutive GDNF delivery.

Conjugating alpha-MSH to an Fc carrier extends serum half-life from minutes to days while preserving melanocortin receptor binding affinity.

Segmented dendrimer surfaces enable targeted drug delivery while reducing synthesis complexity and cytotoxicity.

Kv1.3 antagonists block potassium channels in nociceptive fibers, reducing pain perception without triggering opioid addiction pathways.

A dual microparticle system delivers antigens and immunomodulatory agents to induce antigen-specific immune tolerance.

Monoquaternary ammonium salts selectively bind to nicotinic acetylcholine receptor subtypes to modulate neurotransmitter release.

Codon optimization increases MeCP2 protein yield in E. coli, bypassing insertional mutagenesis risks associated with gene therapy.

Inhibiting 5-LOX and COX-2 restores blood-brain barrier function, reducing vascular inflammation and treating epilepsy in non-responsive patients.

Optimized Sideritis extraction balances yield and stability to improve cognitive function.

Segmented Clec9a binding agents recruit dendritic cells to tumors while preserving native signaling capability.